Radiolanthanides Device Production

149Pm, 166Ho, 161Tb and 177Lu conjugated to chemical agents (monoclonal antibodies, polypeptide, etc.) have the appropriate decay characteristics for imaging and therapeutic studies and conse-quently the potential to be useful in radiotherapy and diagnosis. These carrier-free radioisotopes can be produced by neutron irradiation of a lanthanide target followed by β − decay, and a post-erior radiochemical separation of the daughter radionuclide from macro-amounts of the parent target. In order to produce carrier free 149Pm, 161Tb, 166Ho and 177Lu for radiotherapy, with a ra-dionuclide purity of more than 99.9%, a device production was developed based on separation of Nd/Pm, Gb/Tb, Dy/Ho and Yb/Lu by extraction chromatography